切换至 "中华医学电子期刊资源库"

中华消化病与影像杂志(电子版) ›› 2021, Vol. 11 ›› Issue (02) : 72 -77. doi: 10.3877/cma.j.issn.2095-2015.2021.02.006

所属专题: 文献

综述

贲门失弛缓症的诊断与治疗研究进展
路菲凡1, 李昌达1, 史永军1,()   
  1. 1. 250021 济南,山东第一医科大学附属省立医院消化内科
  • 收稿日期:2020-06-11 出版日期:2021-04-01
  • 通信作者: 史永军
  • 基金资助:
    山东省重点研发计划(2016GSF201002); 济南市科技计划(201613003)

Research progress on diagnosis and treatment of achalasia

Feifan Lu1, Changda Li1, Yongjun Shi1,()   

  1. 1. Department of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, China
  • Received:2020-06-11 Published:2021-04-01
  • Corresponding author: Yongjun Shi
引用本文:

路菲凡, 李昌达, 史永军. 贲门失弛缓症的诊断与治疗研究进展[J]. 中华消化病与影像杂志(电子版), 2021, 11(02): 72-77.

Feifan Lu, Changda Li, Yongjun Shi. Research progress on diagnosis and treatment of achalasia[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2021, 11(02): 72-77.

贲门失弛缓症(AC)作为原发性食管动力障碍性疾病的一种,以食管下段括约肌松弛功能受损、食管蠕动减弱或消失为主要特征,年发病率为1/100 000~3/100 000,临床表现以吞咽困难最为常见。食管测压法为其诊断金标准,另外还有内镜检查、食管钡餐造影检查等诊断方法。目前发病机制尚未明确,临床上可通过药物治疗、肉毒杆菌毒素注射、气囊扩张术、食管支架植入术、腹腔镜下Heller肌切开术、经口内镜下肌切开术等进行治疗。

Achalasia (AC) is a primary esophageal motility disorder characterized by impaired relaxation of the lower esophageal sphincter and absent or decreased peristalsis of the esophageal which annual incidence is about 1/100 000-3/100 000. The most common clinical manifestation of AC is dysphagia. At present, the esophageal manometry has become the gold standard for the diagnosis of AC. In addition, diagnostic methods of AC include endoscopy and X-ray barium meal. The pathogenesis of achalasia is not fully clarified, treatment modalities include pharmacological therapy, botulinum toxin injection, balloon dilatation, esophageal stents therapy, laparoscopic Heller myotomy, and per-oral endoscopic myotomy.

1
Von Renteln D, Fuchs KH, Fockens P, et al. Peroral endoscopic myotomy for the treatment of achalasia: an international prospective multicenter study [J]. Gastroenterology, 2013, 145(2): 309-311.
2
Tuason J, Inoue H. Current status of achalasia management: a review on diagnosis and treatment [J]. J Gastroenterol, 2017, 52(4): 401-406.
3
Islam S. Achalasia [J]. Semin Pediatr Surg, 2017, 26(2): 116-120.
4
Gockel I, Bohl JR, Eckardt VF, et al. Reduction of interstitial cells of Cajal (ICC) associated with neuronal nitric oxide synthase (n-NOS) in patients with achalasia [J]. Am J Gastroenterol, 2008, 103(4): 856-864.
5
Ruiz-de-León A, Mendoza J, Sevilla-Mantilla C, et al. Myenteric antiplexus antibodies and class Ⅱ HLA in achalasia [J]. Dig Dis Sci, 2002, 47(1): 15-19.
6
Boeckxstaens GE. Achalasia: virus-induced euthanasia of neurons? [J]. Am J Gastroenterol, 2008, 103(7): 1610-1612.
7
Becker J, Niebisch S, Ricchiuto A, et al. Comprehensive epidemiological and genotype-phenotype analyses in a large European sample with idiopathic achalasia [J]. Eur J Gastroenterol Hepatol, 2016, 28(6): 689-695.
8
Jung DH, Park H. Is Gastroesophageal Reflux Disease and Achalasia Coincident or Not? [J]. J Neurogastroenterol Motil, 2017, 23(1): 5-8.
9
Hulselmans M, Vanuytsel T, Degreef T, et al. Long-term outcome of pneumatic dilation in the treatment of achalasia [J]. Clin Gastroenterol Hepatol, 2010, 8(1): 30-35.
10
Akaishi T, Nakano T, Machida T, et al. Clinical Usefulness of Endoscopy, Barium Fluoroscopy, and Chest Computed Tomography for the Correct Diagnosis of Achalasia [J]. Intern Med, 2020, 59(3): 323-328.
11
Vela MF. Management strategies for achalasia [J]. Neurogastroenterol Motil, 2014, 26(9): 1215-1221.
12
陈秀秉. 贲门失弛缓症的诊断和治疗进展 [J]. 广西医科大学学报, 2019, 36(3): 479-483.
13
杨烁,徐洪雨. 贲门失驰缓症的诊断与治疗的进展及未来前景 [J]. 胃肠病学和肝病学杂志, 2020, 29(4): 462-465.
14
Gupta P, Debi U, Sinha SK, et al. Primary versus secondary achalasia: New signs on barium esophagogram [J]. Indian J Radiol Imaging, 2015, 25(3): 288-295.
15
Kachala SS, Rice TW, Baker ME, et al. Value of routine timed barium esophagram follow-up in achalasia after myotomy [J]. J Thorac Cardiovasc Surg, 2018, 156(2): 871-877.
16
Dimitriu A, Gheorghe C. High Resolution Manometry-A Mandatory Examination in the Pre and Postoperative Assessment of Patients with Achalasia [J]. Chirurgia (Bucur), 2018, 113(1): 61-69.
17
Salvador R, Costantini M, Zaninotto G. The preoperative manometric pattern predicts the outcome of surgical treatment for esophageal achalasia [J]. J Gastrointest Surg, 2010, 14(11): 1635-1645.
18
钟江利,王红,杜胜奇,等. 诊断贲门失弛缓症——远远不止食管测压 [J]. 医学争鸣, 2020, 11(1): 58-60.
19
Averbukh LD, Tadros M. The Role of Automatically Generated Chicago Classification in Delayed Achalasia Diagnosis [J]. ACG Case Rep J, 2020, 7(3): e00345.
20
Annese V, Bassotti G. Non-surgical treatment of esophageal achalasia [J]. World J Gastroenterol, 2006, 12(36): 5763-5766.
21
Boeckxstaens GE, Zaninotto G, Richter JE. Achalasia [J]. Lancet, 2014, 383(9911): 83-93.
22
Pandolfino JE, Gawron AJ. Achalasia: a systematic review [J]. JAMA, 2015, 313(18): 1841-1852.
23
Smith I, Kahaleh M. An Update on Current Management Strategies for Achalasia and Future Perspectives [J]. J Clin Gastroenterol, 2018, 52(4): 277-286.
24
Campos GM, Vittinghoff E, Rabl C, et al. Endoscopic and surgical treatments for achalasia: a systematic review and meta-analysis [J]. Ann Surg, 2009, 249(1): 45-57.
25
Jung HE, Lee JS, Lee TH, et al. Long-term outcomes of balloon dilation versus botulinum toxin injection in patients with primary achalasia [J]. Korean J Intern Med, 2014, 29(6): 738-745.
26
Schlottmann F, Patti MG. Esophageal achalasia: current diagnosis and treatment [J]. Expert Rev Gastroenterol Hepatol, 2018, 12(7): 711-721.
27
Galassi G, Orlandi C, Valzania F, et al. Botulin toxin type A (BTA) for esophageal achalasia: a double-edged sword [J]. Int J Colorectal Dis, 2011, 26(8): 1079-1080.
28
Tack J, Zaninotto G. Therapeutic options in oesophageal dysphagia [J]. Nat Rev Gastroenterol Hepatol, 2015, 12(6): 332-341.
29
van Hoeij FB, Prins LI, Smout AJPM, et al. Efficacy and safety of pneumatic dilation in achalasia: A systematic review and meta-analysis [J]. Neurogastroenterol Motil, 2019, 31(7): e13548.
30
Zhu YQ, Cheng YS, Tang GY, et al. Comparison of temporary stent insertion with pneumatic dilation of the same diameter in the treatment of achalasia patients: a retrospective study [J]. J Gastroenterol Hepatol, 2010, 25(3): 499-505.
31
Zaninotto G, Leusink A, Markar SR. Management of achalasia in 2019 [J]. Curr Opin Gastroenterol, 2019, 35(4): 356-362.
32
杨艳,于皆平,李欢,等. 内镜下气囊扩张治疗贲门失弛缓症81例 [J]. 世界华人消化杂志, 2007, 15(9): 1024-1026.
33
Song HY, Jung HY, Park SI, et al. Covered retrievable expandable nitinol stents in patients with benign esophageal strictures: initial experience [J]. Radiology, 2000, 217(2): 551-557.
34
易理军. 内镜下食管支架与气囊扩张治疗贲门失弛缓症的疗效比较 [J]. 医学理论与实践, 2020, 33(10): 1617-1618.
35
Zhao JG, Li YD, Cheng YS, et al. Long-term safety and outcome of a temporary self-expanding metallic stent for achalasia: a prospective study with a 13-year single-center experience [J]. Eur Radiol, 2009, 19(8): 1973-1980.
36
李弼民,朱萱,舒徐,等. 贲门失弛缓症可回收支架置入治疗22例分析 [J]. 中国内镜杂志, 2014, 20(10): 1078-1081.
37
Chan MQ, Balasubramanian G. Esophageal Dysphagia in the Elderly [J]. Curr Treat Options Gastroenterol, 2019, 17(4): 534-553.
38
Roller JE, de la Fuente SG, DeMaria EJ, et al. Laparoscopic Heller myotomy using hook electrocautery: a safe, simple, and inexpensive alternative [J]. Surg Endosc, 2009, 23(3): 602-605.
39
Schlottmann F, Luckett DJ, Fine J, et al. Laparoscopic Heller Myotomy Versus Peroral Endoscopic Myotomy (POEM) for Achalasia: A Systematic Review and Meta-analysis [J]. Ann Surg, 2018, 267(3): 451-460.
40
Park CH, Jung DH, Kim DH, et al. Comparative efficacy of per-oral endoscopic myotomy and Heller myotomy in patients with achalasia: a meta-analysis [J]. Gastrointest Endosc, 2019, 90(4): 546-558.
41
Chen Z, Bessell JR, Chew A, et al. Laparoscopic cardiomyotomy for achalasia: clinical outcomes beyond 5 years [J]. J Gastrointest Surg, 2010, 14(4): 594-600.
42
Khashab MA, Messallam AA, Onimaru M, et al. International multicenter experience with peroral endoscopic myotomy for the treatment of spastic esophageal disorders refractory to medical therapy (with video) [J]. Gastrointest Endosc, 2015, 81(5): 1170-1177.
43
Tsiaoussis J, Pechlivanides G, Gouvas N, et al. Patterns of esophageal acid exposure after laparoscopic Heller's myotomy and Dor's fundoplication for esophageal achalasia [J]. Surg Endosc, 2008, 22(6): 1493-1499.
44
王爽,刘冰熔. 贲门失弛缓症的研究进展 [J]. 世界华人消化杂志, 2013, 21(1): 75-81.
45
Parsa N, Khashab MA. POEM in the Treatment of Esophageal Disorders [J]. Curr Treat Options Gastroenterol, 2018, 16(1): 27-40.
46
曾斌,胡光胜,周伟伟,等. 经口内镜下肌切开术治疗贲门失弛缓症临床疗效和并发症的分析 [J]. 中国内镜杂志, 2016, 22(7): 26-30.
47
Brewer Gutierrez OI, Moran RA, Familiari P, et al. Long-term outcomes of per-oral endoscopic myotomy in achalasia patients with a minimum follow-up of 4 years: a multicenter study [J]. Endosc Int Open, 2020, 8(5): E650-E655.
48
Inoue H, Sato H, Ikeda H, et al. Per-Oral Endoscopic Myotomy: A Series of 500 Patients [J]. J Am Coll Surg, 2015, 221(2): 256-264.
49
Li QL, Wu QN, Zhang XC, et al. Outcomes of per-oral endoscopic myotomy for treatment of esophageal achalasia with a median follow-up of 49 months [J]. Gastrointest Endosc, 2018, 87(6): 1405-1412.
50
Stavropoulos SN, Modayil RJ, Friedel D, et al. The International Per Oral Endoscopic Myotomy Survey (IPOEMS): a snapshot of the global POEM experience [J]. Surg Endosc, 2013, 27(9): 3322-3338.
51
Repici A, Fuccio L, Maselli R, et al. GERD after per-oral endoscopic myotomy as compared with Heller's myotomy with fundoplication: a systematic review with meta-analysis [J]. Gastrointest Endosc, 2018, 87(4): 934-943.
52
Tyberg A, Choi A, Gaidhane M, et al. Transoral incisional fundoplication for reflux after peroral endoscopic myotomy: a crucial addition to our arsenal [J]. Endosc Int Open, 2018, 6(5): E549-E552.
53
Inoue H, Ueno A, Shimamura Y, et al. Peroral endoscopic myotomy and fundoplication: a novel NOTES procedure [J]. Endoscopy, 2019, 51(2): 161-164.
[1] 杨水华, 何桂丹, 覃桂灿, 梁蒙凤, 罗艳合, 李雪芹, 唐娟松. 胎儿孤立性完全型肺静脉异位引流的超声心动图特征及高分辨率血流联合时间-空间相关成像的应用[J]. 中华医学超声杂志(电子版), 2023, 20(10): 1061-1067.
[2] 蒋佳纯, 王晓冰, 陈培荣, 许世豪. 血清学指标联合常规超声及超声造影评分诊断原发性干燥综合征的临床价值[J]. 中华医学超声杂志(电子版), 2023, 20(06): 622-630.
[3] 衣晓丽, 胡沙沙, 张彦. HER-2低表达对乳腺癌新辅助治疗疗效及预后的影响[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 340-346.
[4] 谭巧, 苏小涵, 侯令密, 黎君彦, 邓世山. 乳腺髓样癌的诊治进展[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 366-368.
[5] 杨小菁, 姜瑞瑞, 石玉香, 王静静, 李长天. 乳腺孤立性纤维性肿瘤一例[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 375-377.
[6] 冯雪园, 韩萌萌, 马宁. 乳腺原发上皮样血管内皮瘤一例[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 378-380.
[7] 彭旭, 邵永孚, 李铎, 邹瑞, 邢贞明. 结肠肝曲癌的诊断和外科治疗[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 108-110.
[8] 马伟强, 马斌林, 吴中语, 张莹. microRNA在三阴性乳腺癌进展中发挥的作用[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 111-114.
[9] 陈垚, 徐伯群, 高志慧. 改良式中间上入路根治术治疗甲状腺癌的有效性安全性研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 619-622.
[10] 袁媛, 赵良平, 刘智慧, 张丽萍, 谭丽梅, 閤梦琴. 子宫内膜癌组织中miR-25-3p、PTEN的表达及与病理参数的关系[J]. 中华临床医师杂志(电子版), 2023, 17(9): 1016-1020.
[11] 陆志峰, 周佳佳, 梁舒. 虚拟现实技术在治疗弱视中的临床应用研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(08): 891-895.
[12] 李田, 徐洪, 刘和亮. 尘肺病的相关研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(08): 900-905.
[13] 岳瑞雪, 孔令欣, 郝鑫, 杨进强, 韩猛, 崔国忠, 王建军, 张志生, 孔凡庭, 张维, 何文博, 李现桥, 周新平, 徐东宏, 胡崇珠. 乳腺癌HER2蛋白表达水平预测新辅助治疗疗效的真实世界研究[J]. 中华临床医师杂志(电子版), 2023, 17(07): 765-770.
[14] 周婷, 孙培培, 张二明, 安欣华, 向平超. 北京市石景山区40岁及以上居民慢性阻塞性肺疾病诊断现状调查[J]. 中华临床医师杂志(电子版), 2023, 17(07): 790-797.
[15] 符梅沙, 周玉华, 李慧, 薛春颜. 淋巴细胞免疫治疗对复发性流产患者外周血T淋巴细胞亚群分布与PD1/PD-L1表达的影响及意义[J]. 中华临床医师杂志(电子版), 2023, 17(06): 726-730.
阅读次数
全文


摘要